These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 32525068

  • 21. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO, Fukumori T, Daizumoto K, Fukawa T, Kohzuki M, Kowada M, Kusuhara Y, Mori H, Nakatsuji H, Takahashi M, Kanayama HO.
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [Abstract] [Full Text] [Related]

  • 22. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
    Yan J, Xie B, Capodice JL, Katz AE.
    Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
    Naito R, Kano H, Shimada T, Makino T, Kadomoto S, Iwamoto H, Yaegashi H, Izumi K, Kadono Y, Nakata H, Saito Y, Goto M, Nakagawa-Goto K, Mizokami A.
    Prostate; 2021 Apr; 81(5):295-306. PubMed ID: 33493355
    [Abstract] [Full Text] [Related]

  • 30. Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.
    Diao X, Chen X, Pi Y, Zhang Y, Wang F, Liu P, Gao Y, Wang X, Yang S, Lu S.
    Oncol Rep; 2018 Aug; 40(2):1174-1184. PubMed ID: 29917167
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H, Sekine Y, Oka D, Miyazawa Y, Arai S, Koike H, Matsui H, Shibata Y, Suzuki K.
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
    Sasaki T, Yoshikawa Y, Kageyama T, Sugino Y, Kato M, Masui S, Nishikawa K, Inoue T.
    Prostate; 2023 Mar; 83(4):364-375. PubMed ID: 36479717
    [Abstract] [Full Text] [Related]

  • 35. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
    Tovar C, Higgins B, Kolinsky K, Xia M, Packman K, Heimbrook DC, Vassilev LT.
    Mol Cancer; 2011 May 03; 10():49. PubMed ID: 21539745
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
    Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.
    Mol Cancer Ther; 2013 May 03; 12(5):567-76. PubMed ID: 23493310
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.